GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
Posted inCardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.
Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden
Posted inCardiology Internal Medicine news

Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden

A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidity should not be a barrier to invasive rhythm control strategies.
Cryoballoon Ablation Is Non‑Inferior to Radiofrequency for 1‑Year Arrhythmia Control in Persistent AF — but Left Atrium Shrinks Less: Insights from the CRRF‑PeAF Trial
Posted inCardiology news

Cryoballoon Ablation Is Non‑Inferior to Radiofrequency for 1‑Year Arrhythmia Control in Persistent AF — but Left Atrium Shrinks Less: Insights from the CRRF‑PeAF Trial

The randomized CRRF‑PeAF trial (n=499) found cryoballoon pulmonary vein isolation non‑inferior to radiofrequency ablation for 1‑year atrial tachyarrhythmia recurrence in persistent atrial fibrillation, but radiofrequency produced greater left atrial reverse remodelling.
Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin
Posted inCardiology Neurology news

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while numerically more major bleeding occurred with rivaroxaban.